<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02409186</url>
  </required_header>
  <id_info>
    <org_study_id>NXCEL1311</org_study_id>
    <nct_id>NCT02409186</nct_id>
  </id_info>
  <brief_title>A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>A Randomized, Controlled, Double-blind Study to Evaluate Efficacy and Survival of Combining Nimotuzumab Plus Concurrent Chemo-radiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Cancer Hospital and Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Cancer Hospital and Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Esophageal cancer is the sixth leading cause of cancer death in worldwide. Over the past 2
      decades, well-designed clinical trials have documented the clinical benefits of combination
      of chemotherapy and radiation for localized esophageal cancer, either as primary therapy or
      in neoadjuvant setting. Paclitaxel, a radiation sensitizer, has important single-agent
      activity in esophageal cancer. Paclitaxel-based chemoradiation has been the framework for the
      recent Radiation Therapy Oncology Group (RTOG) trials of nonoperative management of
      esophageal cancer. Accumulating clinical evidence suggests that Epidermal Growth Factor
      Receptor (EGFR) represents a viable target in the treatment of esophageal cancer. EGFR
      expression is associated with poor prognosis. Nimotuzumab binds specifically to EGFR on both
      normal and tumor cells and competitively inhibits the binding of Epidermal Growth Factor
      (EGF) and other ligands, such as Transforming Growth Factor-α (TGF-α). Preclinical models
      have suggested synergy between nimotuzumab, paclitaxel, cisplatin and radiation. For our
      phase II study in locally advanced esophageal squamous cell carcinoma (ESCC), the combination
      of cetuximab and chemoradiotherapy has demonstrated both response and survival benefits.
      Myara et al reported that nimotuzumab plus concurrent chemoradiation therapy (CCRT) was safe
      and provided statistically significant objective response (47.8%) and disease control rate
      (60.9%) in nonresectable ESCC. With all these, the investigators plan to study phase III
      trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint of this study is overall survival, and the primary hypothesis is the
      experimental arm will improve median survival time (MST) from 18.2 month to 28.5 month.
      Assuming bilateral ɑ = 0.05, statistical power of 80%.Each group requires a minimum of 59
      cases. Consider the 20% loss factor.The total sample size is 200 cases.It is 100 cases in
      each group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Over Survival</measure>
    <time_frame>up to 5 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Prosthesis Survival</condition>
  <arm_group>
    <arm_group_label>Nimotuzumab plus chemoradiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nimotuzumab：400mg/w，d1, week 1-7 Paclitaxel：45mg/m2, d1, week 1-7 Cisplatin：20mg/m2, d1, week 1-7 Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo plus chemoradiotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo：400mg/w，d1, week 1-7 Paclitaxel：45 mg/m2, d1, week 1-7 Cisplatin：20 mg/m2, d1, week 1-7 Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimotuzumab</intervention_name>
    <description>400mg/w，d1, week 1-7</description>
    <arm_group_label>Nimotuzumab plus chemoradiotherapy</arm_group_label>
    <other_name>Taixinsheng</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7</description>
    <arm_group_label>Nimotuzumab plus chemoradiotherapy</arm_group_label>
    <arm_group_label>placebo plus chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemoradiotherapy Paclitaxel</intervention_name>
    <description>45 mg/m2, d1, week 1-7</description>
    <arm_group_label>Nimotuzumab plus chemoradiotherapy</arm_group_label>
    <arm_group_label>placebo plus chemoradiotherapy</arm_group_label>
    <other_name>Paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemoradiotherapy Cisplatin</intervention_name>
    <description>20 mg/m2, d1, week 1-7</description>
    <arm_group_label>Nimotuzumab plus chemoradiotherapy</arm_group_label>
    <arm_group_label>placebo plus chemoradiotherapy</arm_group_label>
    <other_name>Cisplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>400mg/w，d1, week 1-7</description>
    <arm_group_label>placebo plus chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent prior to study entry

          2. age：18-70 years

          3. Histopathology confirmed primary esophageal squamous cell carcinoma, meet one of the
             following criteria (AJCC Staging System，2009，Seventh Edition):Cervical esophageal
             carcinoma(stage II-III);upper thoracic esophageal cancer or chest esophageal cancer
             that is unsuitable or refuse surgery (stage II-III)

          4. The existence of measurable lesions (according to Response Evaluation Criteria in
             Solid Tumors 1.1)

          5. Eastern Cooperative Oncology Group（ECOG）Performance status of 0-1

          6. Possible semi-liquid diet

          7. If there is a risk of pregnancy, male and female subjects must be effective
             contraception during treatment

          8. Normal bone marrow reserve: neutrophil (ANC) count≥1500/mm3,platelet count≥100,000
             /mm3, hemoglobin≥5.6mmol/L(9g/dL)

          9. Normal renal function: serum creatinine≤1.5mg/dl and/or calculated creatinine
             clearance≥ 60ml/min

         10. Normal hepatic function: bilirubin level≤1.5×ULN, alanine aminotransferase aspartate
             transaminase（ASAT）&amp; ALST≤1.5×ULN

         11. Subjects tumor tissue available for the relevant biomarker detection

        Exclusion Criteria:

          1. Previous chest radiotherapy, systemic chemotherapy, and major esophageal surgery

          2. Concurrent chronic systemic immune therapy, targeted therapy, anti-vascular
             endothelial growth factor（VEGF）therapy or EGFR-pathway targeting therapy not indicated
             in this study protocol

          3. Multiple primary carcinomas of the esophagus

          4. Pregnancy (confirmed by urine β-HCG) or lactation period

          5. Uncontrolled diabetes, hypertension, and severe cardiac or pulmonary disease

          6. There are obvious esophageal ulcers, chest and back more than moderate pain, symptoms
             of esophageal perforation

          7. Unable to comprehend the study requirements or who are not likely to comply with the
             study requirements

          8. Patients with distant metastasis

          9. Patients with other malignant disease, except for curable non-melanoma skin cancer,
             cervical carcinoma in situ or malignant disease cure for≥5 years

         10. Known grade 3 or 4 allergic reaction to any of the study treatment

         11. Peripheral neuropathy &gt; grade 1

         12. Participation in another clinical study within the past 30 days

         13. Significant disease which, in the investigator's opinion, would exclude the patient
             from the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinming Yu, Ph.D, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong Cancer Hospital and Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xue Meng, Ph.D, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Shandong Cancer Hospital and Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jinming Yu, Ph.D, M.D</last_name>
    <phone>13806406293</phone>
    <email>jn7984729@public.jn.sd.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lvhua Wang</last_name>
      <phone>13601283715</phone>
      <email>wlhwq@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Zongmei Zhou</last_name>
      <phone>13801389769</phone>
      <email>zhouzongmei2013@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lvhua Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zongmei Zhou</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guangying Zhu</last_name>
      <phone>13717999977</phone>
      <email>zgypu@yahoo.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Anhui Shi</last_name>
      <phone>13901136511</phone>
      <email>anhuidoctor@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Guangying Zhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anhui Shi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of Shantou University Medical College</name>
      <address>
        <city>Shantou</city>
        <state>Guangdong</state>
        <zip>515041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhixiong Lin</last_name>
      <phone>13829638278</phone>
      <email>zxlin5@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhining Yang</last_name>
      <phone>13750443575</phone>
      <email>36407342@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zhixiong Lin</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhining Yang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Guangxi Zhuang Autonomous Region Cancer Hospita</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaodong Zhu</last_name>
      <phone>13978873616</phone>
      <email>zhuxiaodong83@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Long Chen</last_name>
      <phone>13977129168</phone>
      <email>clong6@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xiaodong Zhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Long Chen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Zunyi Medical College</name>
      <address>
        <city>Zunyi</city>
        <state>Guizhou</state>
        <zip>563099</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hu Ma</last_name>
      <phone>18385034657</phone>
      <email>mahuab@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiaoli Gou</last_name>
      <phone>15121201843</phone>
      <email>526392247@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hu Ma</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaoli Gou</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fourth Hospital of Hebei Medical University Tumor</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>50011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chun Han</last_name>
      <phone>13831105846</phone>
      <email>hanchun@yahoo.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Jun Wang</last_name>
      <phone>13931182128</phone>
      <email>wangjunzr@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Chun Han</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianhua Wang</last_name>
      <phone>13938278827</phone>
      <email>huajianye@sina.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yongshun Chen</last_name>
      <phone>15286831671</phone>
      <email>yongshun2007@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jianhua Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yongshun Chen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Zhu</last_name>
      <phone>15380882705</phone>
      <email>zhujdr@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Hong Ji</last_name>
      <phone>18625155033</phone>
      <email>dr_jihong@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jun Zhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hong Ji</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Jiangsu University</name>
      <address>
        <city>Zhenjiang</city>
        <state>Jiangsu</state>
        <zip>212013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dai Chunhua, PhD</last_name>
      <phone>13952850012</phone>
    </contact>
    <investigator>
      <last_name>Dai Chunhua, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guang Li</last_name>
      <phone>13804058616</phone>
      <email>13804058616@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Jun Dang</last_name>
      <phone>13898150850</phone>
      <email>dangjunsy@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Guang Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun Dang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shandong Cancer Hospital and Institute</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xue Meng, Ph.D, M.D</last_name>
      <phone>86-531-67626142</phone>
      <email>mengxue5409@126.com</email>
    </contact>
    <investigator>
      <last_name>Xue Meng, Ph.D, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renji Hospital Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ming Ye</last_name>
      <phone>13901814744</phone>
      <email>renjiyeming@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Xin Xu</last_name>
      <phone>13917978366</phone>
      <email>157198711@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ming Ye</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xin Xu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Zhejiang Province</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Senxiang Yan</last_name>
      <phone>13957162839</phone>
      <email>yansenxiang@zju.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Haogang Yu</last_name>
      <phone>13516721749</phone>
      <email>jusn3@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Senxiang Yan</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Haogang Yu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Chen</last_name>
      <phone>18758875572</phone>
      <email>chenming@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yujin Xu</last_name>
      <phone>13858037993</phone>
      <email>xuyj@zjcc.org.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Ming Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yujin Xu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2014</study_first_submitted>
  <study_first_submitted_qc>April 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2015</study_first_posted>
  <last_update_submitted>April 19, 2016</last_update_submitted>
  <last_update_submitted_qc>April 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Cancer Hospital and Institute</investigator_affiliation>
    <investigator_full_name>Jinming Yu</investigator_full_name>
    <investigator_title>President</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Prosthesis Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

